Intracellular Pharmacodynamics: a Journey from Cell biology to the Design of New Chemotherapeutic Agents Paul M. Tulkens, MD, PhD Cellular and Molecular.

Slides:



Advertisements
Similar presentations
Listeria monocytogenes phagocytic strategies. Dr. Carmen Alvarez-Dominguez. Immunology Dpt. Hospital Santa Cruz de Liencres- IFIMAV/IES Zapatón. Cantabria.
Advertisements

Immunity to bacteria Barrier defenses of human body.
Animal Model PK/PD: A Tool for Drug Development
The Immune System Non-Specific Immunity. What You Should Know The human body has the capacity to protect itself against pathogens, some toxins and cancer.
Karmanshah, Iran, 24 May 20111st International and 12th Iranian Congress of Microbiology 1 Hunting intracellular bacteria with antibiotics Paul M. Tulkens,
Immunity to microbes (mechanisms of defense against
5/20/2015ISAP Is the cellular accumulation of antibiotics a predictive factor for intracellular efficacy ? Sandrine Lemaire Université catholique.
Obligate Intracellular Organisms. Bacterial Intracellular Organisms Intracellular organism Lives in a phagosome & prevents phagolysosomal fusion Escapes.
Pharmacodynamics of Antibiotics
“Emerging infections, the re-emergence of infectious diseases previously considered to be under control, and the alarming trend of antibiotic resistance….require.
Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.
Inhibiting Microbial Growth in vivo CLS 212: Medical Microbiology.
PK/PD - ICC - Manila, June 5th, The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ? Paul.
Burton's Microbiology for the Health Sciences Chapter 9
Clinical implications of tissue concentrations Ursula Theuretzbacher Center for Anti-Infective Agents, Vienna, Austria Clinical Issues of PK/PD, ECC, Firenze.
Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.
Pharmacodynamic Indices Canisius-Wilhelmina Hospital Nijmegen, The Netherlands Johan W Mouton.
THE IMMUNE RESPONSE AGAINST INTRACELLULAR BACTERIA
Antimicrobials - Quinolones & Fluoroquinolones Antimicrobials - Quinolones & Fluoroquinolones Pharmacology -1 DSX 215 DSX 215 Dr/ Abdulaziz Saeedan Pharmacy.
Bacterial Pathogenesis İ. Çağatay Acuner M.D., Clinical Microbiologist, Associate Professor Department of Microbiology Faculty of Medicine, Yeditepe University,
PRINCIPLES OF ANTIBIOTIC THERAPY
MACROLIDES: pharmacokinetics and pharmacodynamics
Hunting intracellular bacteria with antibiotics
Bacterial persistence
Setting-up a model of intracellular infection by Pseudomonas aeruginosa for the pharmacodynamic evaluation of antibiotic activity. J. Buyck1, O. Jolois2,
studies with Caco-2 cells and THP-1 macrophages
Protein Synthesis Inhibitors
Activity of tobramycin in combination with clarithromycin
Comparison of the intracellular and extracellular activities of approved and novel antistaphylococcal antibiotics using a pharmacodynamic model exploring.
Intracellular antibiotics and Listeria monocytogenes
Françoise Van Bambeke & Paul M. Tulkens
In vitro pharmacodynamic models for the study of antibiotic activity against bacterial biofilms Françoise Van Bambeke, PharmD, PhD Pharmacologie cellulaire.
Intracellular Antibiotics : what does it (really) mean ?
Activity of 9 antibiotics against intracellular forms of S. pneumoniae
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ? Paul M. Tulkens Cellular and Molecular.
Azalides revisited: Why the single dose ? The pharmacologist's answer … Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of.
This poster will be made available for download after the meeting at :
Co-medications Improve Moxifloxacin (MXF) Activity in Models of Pneumococcal Naïve and Induced Biofilms (BF) N. M. Vandevelde1, M. Van Obbergh1, P.M. Tulkens1,
Background and objectives
Aminoglycoside nephrotoxicity: from molecular pharmacology and pathology to some applications Paul M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire.
Antibiotic efflux pumps in eucaryotic cells: consequences for activity against intracellular bacteria Françoise Van Bambeke on behalf of J.M. Michot,
Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology Unit
Extracellular activity Intracellular activity
Abstract Results Methods Background Conclusions References
52 - Antimicrobials Radezolid (RX-1741), a Novel Oxazolidinone, Accumulates Extensively within Human Macrophages and PMNs and Shows Activity towards.
EV0626 Cellular pharmacokinetics of gepotidacin (GSK )
A-045 Identification of the Efflux Transporter of Ciprofloxacin in Murine Macrophages: Studies with Ciprofloxacin-Resistant Cells Béatrice Marquez, Nancy.
Difference log CFU from time 0
Electron microscopy: intracellular infection of THP-1 by S. aureus
Immunology & Public Health
An overview of bacterial mechanisms for pathogenicity.
Immunology & Public Health
Antibiotics in 2005: Which one do we need to use and when ?
Rega Institute : my research contacts …
Intracellular antibiotics
Françoise Van Bambeke, Dr Sc. Pharm, Agr. Ens. Sup.
Intracellular models of infection to evaluate antibiotic activity
TLR Signaling Is Required for Salmonella typhimurium Virulence
Models of Intracellular Antibiotic Transport
Chemotherapy and PK/PD of intracellular infections
Pharmacodynamic indices in targeting therapy of critical infections
Setting-up of a 24 h model to evaluate the activity of antibiotics against intracellular forms of S. aureus infection C. Seral, M. Barcia-Macay, F. Van.
Fig. 2 Systemically released inflammatory factors directly affect HSC-e cell fate. Systemically released inflammatory factors directly affect HSC-e cell.
IMMUNE RESPONSE TO MYCOBACTERIAL INFECTION
Legionella Reveal Dendritic Cell Functions that Facilitate Selection of Antigens for MHC Class II Presentation  Annie L Neild, Craig R Roy  Immunity 
Are intracellular drug concentrations relevant for efficacy
Volume 4, Issue 6, Pages (December 2008)
Volume 37, Issue 1, Pages (July 2012)
Key Area 3.5: Non-Specific Body Defences
Intracellular Antibody Neutralizes Listeria Growth
Presentation transcript:

Intracellular Pharmacodynamics: a Journey from Cell biology to the Design of New Chemotherapeutic Agents Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels, Belgium & International Society of Antiinfective Pharmacology Advances in the Pharmacology of Antiinfective Therapy, Bangalore, India, January 20-22, 2000

What is Intracellular Infection ? The Cell (black box) antibioticbacteria

These they are… è OBLIGATORY OR MAINLY INTRACELLULAR: Ørespiratory infections (pneumopathies): Chlamydia pneumoniae: 10% in children Legionella pneumophila: frequent if immunosuppression Mycobacterium spp.:frequent if immunosuppression Øsexually transmitted diseases Chlamydia trachomatis: most common pathogen Ø CNS infections + other sites: Listeria monocytogenes: pregnant women; immunosuppression è FACULTATIVE OR MAINLY EXTRACELLULAR: Ø digestive tract infections Salmonella spp., Shigella spp. Ø respiratory, cutaneous, etc…tract infections Streptococcus spp., Staphylococcus spp.

1. where are the bacteria ? 2. which antibiotics accumulate in cells ? 3. where are antibiotics located ? 4. what is the intracellular expression of activity ? 5. what is the bacterial responsiveness ? 6. cooperation with the cell own defenses and cytokines? You need to consider (at least) the following questions:

1st question (and answer) : where do intracellular bacteria sojourn and thrive ? Legionella Chlamydia,... S. aureus Salmonella, M. leprae,... Listeria hly+, Shigella phagosomes phagolysosomes cytosol endosomes

Antibiotics and Intracellular Bacteria : a Bit of Theory Eur. J. Microbiol Infect. Dis. 10: , 1991

2d question (and answer): which antibiotics do accumulate in cells ? beta-lactams:  1x aminoglycosides: <1 to 2 x ansamycins: 2-3 x tetracyclines: 2-4 x fluoroquinolones: x macrolides: 4 to > 100 x

endosomes ? phagosomes ? phagolysososomes macrolides aminoglycosides cytosol fluoroquinolones beta-lactams ansamycins 3d question (and answer) : where are intracellular antibiotics located ?

endosomes phagosomes macrolides: reduced aminoglycosides: very reduced fluoroquinolones: yes ansamycins: excellent beta-lactams: yes 4th question: what are the antibiotic intracellular expressions of activity pH = 7 pH < 6

in endosomes: ? in phagosomes likely to excellent 5th question: what is the bacterial responsiveness to the antibiotics ? pH = 7 pH < 6 in cytosol: excellent in phagolysosomes: very variable

in endosomes: likely in phagosomes likely 6th question [1 of 2] : cooperation with the cell own defenses ? pH = 7 pH < 6 in cytosol: unlikely in phagolysosomes: very variable O 2. - NO. myeloperoxydase acidity, cationic proteins...

6th question [2 of 2] : cooperation or antagonism with the actions of cytokines ? The very black box antibiotic interferons ILx growth fact. TNF...

antibiotics: ampicillin sparfloxacin azithromycin interferon gamma Listeria monocytogenes hly+ and hly-

INTRACELLULAR INFECTION CYCLE OF Listeria monocytogenes hly + from Portnoy et al.

Bacteria are stained with fluorescein (FITC) [green] and cell actin with phalloidin rhodamin [red]; hly + : virulent hly - : non virulent Listeria and Interferon  : confocal microscopy

A: phagocytosis B: escape from vacuole C: surrounded by actin D,E: cells pre-treated with interferon-gamma, L. m. hly+ remains in vacuoles. F,G, H: L.m. hly- remains constantly in vacuoles A = 1 h post infection; B, C, D, F, G = 3 h post infection E, H = 5 h post infection Following the intracellular fate of Listeria m. in EM

control IFN  100 U/ml control IFN  100 U/ml IFN  contains L. monocytogenes hly + in phagosomes and impairs its growth. A: dose-dependency; B: specifity IFN  50 U/ml IFN  100 U/m + anti IFN  IgG

The growth containment of L. monocytogenes caused by IFN  is due to NO and H production...

IFN  and antibiotics... control + IFN + IFN  and LMMA / catalase Intracellular activity: 0 h 5 h log 10 Bacterial growth Bacterial kill

Listeria, ampicillin and Interferon gamma 1. Ampicillin is poorly active against intracellular Listeria; 2. Ampicillin activity is completely defeated when IFN  is present (IFN makes the job !) Why do you keep ampicillin ?  extracellular bacteria  get activity with very large doses

Listeria, fluoroquinolones and Interferon SP + INF  CT SP + INF  + LMMA + catalase sparfloxacin (Ouadrhiri et al, 1999) SP SP + INF  + LMMA + catalase T = 5h AccumulationActivity SP + INF 

Listeria, fluoroquinolones and Interferon 1. Sparfloxacin appears highly active against intracellular Listeria; 2. Sparfloxacin activity is enhanced when IFN  is present (IFN and Sp cooperate !) Why don’t you use fluoroquinolones ?  too low intrinsic activity...

Where published ? Scorneaux et al., Antimicrob. Agents Chemother. 40: , 1996 Ouadrhiri et al., Antimicrob. Agents Chemother. 43: , 1999 Ouadrhiri et al., J. Infect. Dis. 180: , 1999

CN O COOH R C H N O H 2 N CH 3 3 D-alanine beta-lactam

O COOH R ALL beta-lactam have (and must have) a free carboxyl group (or an equivalent acidic group [electron donor]) — at appropriate distance from the C — N bound NC

phagolysososomes pH  5-6 exatracellular pH  7.4 Why do beta-lactams not accumulate in cells (1 of 2) ? cytosol pH  7.2

Why beta-lactams do not accumulate in cells (2 of 2) ? AH A - AH A - AH A - H+H+ H+H+ H+H+

What if you are basic ? B BH + B BH + B BH + H+H+ H+H+ H+H+

O CO- R R To get accumulation, make a basic beta-lactam... NC - NH 2

O CO - NH-CH 2 -CH 2 -CH 2 -N (CH 3 ) 2 R N-(3-dimethylaminopropyl)benzylpenicillamide... NC S CH 3 H

N-(3-dimethylaminopropyl) benzylpenicillamide…  get accumulated in cells (5 to 10-fold  concentrates in lysosomes but…  is inactive because the amide linkage is not splitted by lysosomal enzymes...

O CO - O - CH 2 - X - NH 2 R You need to make a chemically labile ester... NC S CH 3 H

What you can do with old pivampicillin... N S COO CH 3 O 3 H N C O NH 2 O O H 2 C O CC O CH C N S 3 O 3 H N C O NH 2 N S COOH CH 3 O 3 H N C O NH 3 O O H 2 C O CC O CH C N S 3 O 3 H N C O NH 3 ampicillin pivampicillin pH 7 pH <

Old pivampicillin does bring ampicillin in cells... free AMPI PIVA AMPI FROM PIVA CTAMPIPIVA T = 24h (Fan et al, 1997)

Where published ? Renard et al., J. Med. Chem. 29: , 1986 Renard et al., Antimicrob. Agents Chemother. 31: , 1987 Fan et al., Bioorg. Med. Chem. Letters 24: , 1997

Thanks to the crew... Zubida Bumkhalla (beta-lactams [chemistry]) Marie-Béatrice Carlier (macrolides, fluoroquinolones) Huajuan Fan (betlactams [chemistry] ) Christine Renard (beta-lactams) Yousef Ouadrhiri (Listeria, interferon, IL6, fluoroquinolones) Isabelle Paternotte (beta-lactams [chemistry], efflux mech.) Bernard Scorneaux (Listeria, interferon, fluoroquinolones) Etienne Sonveaux (beta-lactams [chemistry] ) Andrée Zenebergh (lincosaminides, macrolides)

But where do they work ? Catholic University of Louvain Faculty of Medicine Brussels, Belgium

But, where is this university? Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Belgium

intracellular pharmacodynamics AUIC postantibiotic effect... population pharmacokinetics tissue concentrations efficacy/toxicity ratios But don’t forget ISAP...

intracellular pharmacodynamics AUIC postantibiotic effect... population pharmacokinetics tissue concentrations efficacy/toxicity ratios And thank you to Bangalore...